The Full Wiki

More info on Agomelatine

Agomelatine: Quiz


Question 1: Antagonism of 5-HT2C results in an enhancement of DA and NE release and activity of frontocortical ________ and adrenergic pathways.
TranylcypromineDopaminergicDopamine reuptake inhibitorMonoamine oxidase inhibitor

Question 2: [4][5] Because of its unique profile, agomelatine has not been associated with weight gain, sexual side effects, sleep problems or withdrawal syndrome; this is in contrast to most ________ and many antidepressants.
MirtazapineSelective serotonin reuptake inhibitorTricyclic antidepressantSerotonin reuptake inhibitor

Question 3: Servier continued to develop the drug and conduct phase III trials in the ________.
DenmarkEuropean UnionEuropean ParliamentGermany

Question 4: In March 2006, Servier announced it had sold the rights to market agomelatine in the United States to ________.
NovartisNestléSyngentaHoffmann–La Roche

Question 5: [11] On 20 November 2008, Valdoxan was given a positive opinion, with restrictions,[12] by the EMEA[11], and was subsequently given marketing authorisation in the ________ on 20 February 2009.
DenmarkEuropean UnionEuropean ParliamentGermany

Question 6: Controlled studies with humans have shown that agomelatine is comparable to paroxetine (Seroxat, Paxil) and sertraline (Lustral, Zoloft), two ________ antidepressants, in the treatment of major depression.
Tricyclic antidepressantMirtazapineSerotonin reuptake inhibitorSelective serotonin reuptake inhibitor

Question 7: Agomelatine (trade names Valdoxan, Melitor, Thymanax) is an ________ developed by the pharmaceutical company Servier.

Question 8: [7] Agomelatine has also demonstrated anxiolytic properties and thus may prove efficacious in the treatment of ________.
Social anxiety disorderMajor depressive disorderAnxiety disorderGeneralized anxiety disorder

Question 9: Agomelatine was discovered and developed by the European ________ company Servier Laboratories Ltd.
Psychoactive drugPharmaceutical drugDrugAntidepressant

Got something to say? Make a comment.
Your name
Your email address